Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis’ oncology chief discusses expectations for Tasigna and outlook for late-stage pipeline.

You may also be interested in...



Tasigna Approval May Be Again Delayed To Allow FDA Advisory Cmte. Review – Novartis

NDA for next-generation chronic myeloid leukemia therapy currently has late October action date, but FDA may convene ODAC to review Tasigna in December.

Tasigna Approval May Be Again Delayed To Allow FDA Advisory Cmte. Review – Novartis

NDA for next-generation chronic myeloid leukemia therapy currently has late October action date, but FDA may convene ODAC to review Tasigna in December.

Spooling Along: Ariad, Merck Get SPA For Phase III Trial Of Oral Deforolimus

Ariad seeking indication in metastatic soft tissue and bone sarcomas, with progression-free survival primary endpoint.

Related Content

Topics

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel